Active Stocks to Watch : Google Inc (NASDAQ:GOOGL), Sony Corp (ADR) (NYSE:SNE), Lexmark International (NYSE:LXK), Paychex (NASDAQ:PAYX), Tile Shop Holdings, Inc. (NASDAQ:TTS),

Google Inc (NASDAQ:GOOGL) has selected HTC Corp to make its upcoming 9-inch Nexus tablet, the Wall Street Journal reported, citing people familiar with the matter. Google Inc (NASDAQ:GOOGL) belongs to Technology sector. Its net profit margin is 20.90% and weekly performance is -2.01%. On last trading day company shares ended up $585.25. Google Inc (NASDAQ:GOOGL)…

Read More

Five Things Which You Didn’t Know About Twitch, Amazon.com, Inc. (NASDAQ:AMZN)’s Recent Acquisition

Amazon.com, Inc. (NASDAQ:AMZN) announced on Monday that it had acquired Twitch for $970 million. What is it about the video game streaming platform that had major companies like Amazon and Google Inc (NASDAQ:GOOGL) vying for its hand? Twitch is an exponentially growing video game live streaming website The operative word here is ‘exponentially growing’. Twitch…

Read More
AMZN NASDAQ AMZN Amazon Inc

Amazon.com, Inc. (NASDAQ:AMZN) Beats Google Inc (NASDAQ:GOOGL) In Race For Video Streaming Website Twitch

Amazon.com, Inc. (NASDAQ:AMZN) announced on Monday that it had acquired the live streaming gaming website Twitch for $970 million in cash. The deal is one of the costliest for the online retailer and is expected to be closed by the end of this year. Amazon chief Jeff Bezos commented that his company and Twitch are…

Read More

Amazon.com, Inc. (NASDAQ:AMZN) All Set To Get Into Google Inc. (NASDAQ:GOOG)’s Territory

Amazon.com, Inc. (NASDAQ:AMZN) is reportedly developing a Google Inc (NASDAQ:GOOGL) AdWords like advertising software. Amazon has already tested the waters with a small ad business on other websites and is making plans to expand the model by employing newer and better ads. While Google is clearly the current market leader in the advertising world, such…

Read More

Stocks in Focus : Sarepta Therapeutics (NASDAQ:SRPT), Google Inc (NASDAQ:GOOGL), B&G Foods Inc. (NYSE:BGS), Repros Therapeutics Inc. (NASDAQ:RPRX), Tejon Ranch (NYSE:TRC)

Chris Garabedian, President and CEO Sarepta Therapeutics, Inc. (NASDAQ:SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference…

Read More